Treatments

*June 2025* Abstract Introduction Dysregulated MET signaling, such as MET overexpression or MET amplification (METamp), is a important mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant lung adenocarcinoma (LUAD). Combination therapy with EGFR TKIs and MET TKIs has revealed efficacy in these patients. This study…

*May 2025* Background: Leptomeningeal metastasis (LM) is an infrequent and challenging site of metastasis in patients with non-small cell lung cancer (NSCLC). Currently, there is no standardized treatment protocol or consensus for managing NSCLC patients with LM. This study aims to comprehensively evaluate the efficacy and safety of targeted therapy in…

*July 2025* First-line treatment with the combination of osimertinib (Tagrisso) in combination with chemotherapy led to a statistically significant and clinically meaningful improvement in overall survival (OS) compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data from…

*July 2025* The FDA has granted fast track designation to the next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310 for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion or exon 21 L858R mutation who experienced disease progression on or after…

*July 2025* In a presentation at the 26th Annual International Lung Cancer Congress, Heather Wakelee, MD, highlighted therapeutic avenues in the second line after the development of resistance to first-line osimertinib (Tagrisso) or combination therapies for patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.1 These included secondary mutation–targeted therapies; chemotherapy-based treatment, including the…

*July 2025* In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the integration of datopotamab deruxtecan (Dato-DXd; Datroway) into the treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC). The recent FDA approval of Dato-DXdoffers a new therapeutic avenue for patients with EGFR-sensitizing mutations in…

*July 2025* Abstract The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped…

*June 2025* Targeted OncologyTM: How did the MARIPOSA trial (NCT04487080) assess patients receiving amivantamab (Rybrevant) plus lazertinib (Lacluze) vs osimertinib (Tagrisso) forinterstitial lung disease (ILD)? Xiuning Le, MD, PhD: I think it's based on both . Nowadays, for ILD in most of the clinical trials, they will take our investigator…

*June 2025* Abstract Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC,…

*July 2025* Highlights --Mutations were more easily detected in CSF than in plasma of NSCLC leptomeningeal metastasis. --Genes enriched in CSF are altered in multiple oncogenic signaling pathways. --CSF exhibits significantly greater copy number variations and missense mutations than plasma. --Furmonertinib combined with bevacizumab, and high-dose pemetrexed for IVC can…